Serum PCSK9 Levels Distinguish Individuals Who Do Not Respond to High-Dose Statin Therapy with the Expected Reduction in LDL-C

Por Taylor, Beth A., Panza, Gregory, Pescatello, Linda S., Chipkin, Stuart, Gipe, Daniel, Shao, Weiping, White, C. Michael, Thompson, Paul D.
Publicado em 2014

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of...

Por Kastelein, John J. P., Robinson, Jennifer G., Farnier, Michel, Krempf, Michel, Langslet, Gisle, Lorenzato, Christelle, Gipe, Daniel A., Baccara-Dinet, Marie T.
Publicado em 2014

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

Por Kastelein, John J.P., Ginsberg, Henry N., Langslet, Gisle, Hovingh, G. Kees, Ceska, Richard, Dufour, Robert, Blom, Dirk, Civeira, Fernando, Krempf, Michel, Lorenzato, Christelle, Zhao, Jian, Pordy, Robert, Baccara-Dinet, Marie T., Gipe, Daniel A., Geiger, Mary Jane, Farnier, Michel
Publicado no Eur Heart J (2015)